Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com. Cepheid is proud to be a part of Danaher. Danaher's science and technology leadership puts Cepheid's solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
Unlock the market timeline & signal feed
New Marketing & PR activity — 8 fresh signals just appeared.
The order this company entered each market — oldest to newest
Field Applications Engineer - Molecular Diagnostics (IVD)
10 active postings
Sign up to see the full signal feed
How Cepheid's international expansion compares to its competitors
CepheidYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 CepheidYou | 9 | 3 | +1200% | 14 | 30 |
Lead Biostatistician, Global Quality, Regulatory, Clinical Affairs
View postingBengaluru East, Karnataka, India · last wk.
Lead Computer Integration Engineer
View postingPenang, Penang, Malaysia · 3w ago
Supplier Development & CM Transfer Engineer
View postingPenang, Penang, Malaysia · 3w ago
☝️ What if every treatment decision started with better diagnostics?🎤 In this Cepheid Talks podcast episode, Dr. Ephraim Tsalik shares his perspective on the evolving role of diagnostics in clinical decision-making and antimicrobial resistance (AMR). 💫 From advancing innovation to enabling more precise, timely care, this conversation explores how diagnostics can help shape better outcomes for both clinicians and patients.Tune in now: https://ow.ly/44zi50Z7oxA ...
Active
C. difficile Is Not Just Another GI Pathogen — Why Testing Strategy MattersHigh rates of asymptomatic colonization mean that how we test for C. difficile directly impacts diagnosis, treatment decisions, antimicrobial exposure, and stewardship outcomes.🎥 Now available on demand:Watch our global expert webinar to explore:• Colonization vs. true infection• The clinical impact of testing strategy• Diagnostic & antimicrobial stewardship• Practical insights for clinicians and labs👉 Access the on‑dem ...
EndedHi %FIRSTNAME%At ESCMID Global 2026, experts explored how diagnostic stewardship, smart molecular panels, and the evolving role of metagenomics are shaping more confident clinical decision‑makingIf you couldn’t attend in Munich, you haven’t missed your opportunity. Catch up on the topics belowAccess the recorded symposium and catch up on your own schedule.
EndedDanaher's five diagnostic companies showcase AI and digital innovations at CCLTA 2025, focusing on laboratory medicine, oncology, and critical care.
Danaher is close to acquiring US medical technology company Masimo for about $10 billion, potentially announcing the deal soon.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Cepheid's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
